Meta-analysis results for all treatments

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament Trials      
clinical deteriorationclinical improvementdeathsviral clearance
mRNA vaccine66-- 0.50 [0.11; 2.28], 2 RCTs, I2=0%
inconclusive result
-
Non replicating viral vector34-- 0.19 [0.06; 0.64], 2 RCTs, I2=0%
moderate degree of certainty
-
first booster dose20-- OBS 0.13 [0.08; 0.24], 6 studies, I2=78%
high degree of certainty
-
Inactivated virus vaccine12-- OBS 0.20 [0.14; 0.28], 1 study, I2=0%
unassessable degree of certainty
-
second booster dose7-- OBS 0.22 [0.17; 0.28], 1 study, I2=0%
unassessable degree of certainty
-
protein subunit vaccine4----
complete primary vaccine series1 OBS 0.45 [0.34; 0.60], 3 studies, I2=66%
unassessable degree of certainty
- OBS 0.16 [0.06; 0.41], 5 studies, I2=79%
high degree of certainty
-
heterologous prime-boost1----
A EFFACER BBV152 (Bharat Biotech, India)0----
A EFFACER Janssen Ad.26.COV2.S vaccine (JNJ-78436725)0----
A EFFACER_ Vero cell0----
A EFFACER_sequential Immunization0----
BCG vaccination0----
CoVLP (MT-2766, Medicago)0----
DNA vaccine0----
ebola vaccine0----
Replicating Viral Vector0----
seasonal influenza vaccines0----
virus-like particles vaccine0----